Condition
Lung Diseases Due to External Agents|Mesothelioma
Estimated Enrollment: 50
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: 2016-0514|NCI-2017-00069
Study First Received: December 28, 2016
Last Updated: April 19, 2017
Estimated Primary Completion Date: April 2022
Primary Outcome Measures:
Disease Control Rate (DCR) in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin|Time to Progression in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin
Sponsors and Collaborators:
M.D. Anderson Cancer Center|Seattle Genetics, Inc.
Website Link: https://ClinicalTrials.gov/show/NCT03007030
